Wound Management Technologies' CellerateRX® Activated Collagen(TM) Debuts at the South African Diabetic Foot Working Group Congress in Cape Town
FORT WORTH, Texas, Aug. 18 Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists. Spiramed will also be exhibiting CellerateRX® at the UBUNTU International Conference-A Global Wound Healing Initiative September 5-8. This conference is hosted by South Africa and endorsed by the Wound Healing Association of Southern Africa. Other supporting organizations include the World Alliance of Wound and Lymphedema Care, World Health Organization, The Lindsay Leg Club Foundation, and Wound International. The programme is focused on assessing the scope of wound care issues in economically challenged countries and proposing strategies and solutions in the area of wound care. They will also be showcasing CellerateRX® at the VASSA 2010 Congress (Vascular Society of Southern Africa) in October.
"We are excited about CellerateRX®'s introduction to the South African market," stated Cathy Bradshaw, President of Wound Care Innovations, a subsidiary of Wound Management Technologies. "According to the World Diabetes Foundation, the estimated number of people with diabetes in South Africa is approximately 840,000, with a projected increase to 1.3 million in the next few years. Statistics show that around 15% of these people will develop a diabetic foot ulcer at some point in their lives. We believe that CellerateRX® can have an enormous impact in the management of the related wounds."
CellerateRX® is registered in South Africa and has assigned NAPPI (National Pharmaceutical Product Interface) codes. It is registered with various South African insurance companies as an authorized product for reimbursement.
For Wound Management Technologies Shareholder Information please call 817-820-7077 or go to http://www.wmgtech.com
About Wound Care Innovations, LLC
Wound Care Innovations, LLC (WCI) is a wholly owned subsidiary of Wound Management Technologies, Inc. (OTC Bulletin Board:WNDM.ob - News) with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida. WCI markets and distributes wound care products to the healthcare market under patented technology licensed to the Company. The Company is positioned and seeks to be a leading provider of wound care products. For more information on CellerateRX®, please visit the WCI web site at http://www.celleraterx.com/ .
About Wound Management Technologies, Inc.
Wound Management Technologies, Inc.'s primary focus is the distribution of its unique, patented collagen product, CellerateRX®, in the $3.2B worldwide advanced wound care market, a market that is growing due to aging populations and the increase of diabetes. Over the past 2 years Wound Management has focused on developing evidenced-based studies on CellerateRX® and gaining physician awareness by participation in key industry conferences. Now Wound Management is focused on expanding sales through partnerships and contracted independent representatives. Wound Management has other advanced biotech products in development for bone wax, bone void fillers and shingles pain reduction as well as a subsidiary focused on eHealth technology for secure healthcare data collaboration and storage. More information can be found on the company's web sites: http://www.wmgtech.com, http://www.celleraterx.com , and http://www.secureehealth.com .
Safe Harbor Statement:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
SOURCE Wound Management Technologies, Inc.
You May Also Like